BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the presentation of clinical data from its open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25–29, 2026, at Firenze Fiera in Florence, Italy.

The presentation titled "A Study of Roluperidone Coadministered with Olanzapine in Patients with Negative Symptoms of Schizophrenia" is being delivered by Michael Davidson, MD, Chief Medical Officer of Minerva Neurosciences and highlights safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings from the trial. The trial was designed to assess potential interactions between roluperidone and a widely used antipsychotic, olanzapine. The trial shows no clinically significant adverse effects, no meaningful pharmacokinetic (PK) changes, and no pharmacodynamic (PD) changes during combined administration.